Combination of vascular disrupting agents and ionizing radiation

Critical Reviews in Oncology/Hematology

Volumn 86, Issue 2, 2013, Pages 143-160

  Clémenson, Céline ^a   Chargari, Cyrus ^a,b   Deutsch, Eric ^a  

^a Institut Gustave Roussy   (France)

^b University of Paris Descartes   (France)

Author keywords

Antiangiogenic agents; CA 4 P; Preclinical rationale; Radiotherapy; Tubulin binding agents; Vascular disrupting agents

Indexed keywords

2 METHOXYESTRA 1,3,5(10),16 TETRAENE 3 CARBOXAMIDE; ANG 501; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BNC 015; BNC 105; C 9; CA 4 P; CARBOPLATIN; CHLORDANE; CISPLATIN; COMBRETASTATIN A1 PHOSPHATE; COMBRETASTATIN A4 PHOSPHATE; DENIBULIN; DOCETAXEL; IRC 083927; LEXIBULIN; MICROTUBULE BINDING AGENT; N [2 [(4 HYDROXYPHENYL)AMINO] 3 PYRIDINYL] 4 METHOXYBENZENESULFONAMIDE; N ACETYLCOLCHINOL PHOSPHATE; OMBRABULIN; PACLITAXEL; PLACEBO; PLINABULIN; SOBLIDOTIN; STX 140; TH 482; UNCLASSIFIED DRUG; UNINDEXED DRUG; VADIMEZAN; VASCULAR TARGETING AGENT; VINBLASTINE;

ADENOCARCINOMA; ANAPLASTIC THYROID CANCER; ANTIPROLIFERATIVE ACTIVITY; BINDING AFFINITY; BRADYCARDIA; BREAST CANCER; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CARDIOTOXICITY; CHEMORADIOTHERAPY; COLON ADENOCARCINOMA; COLON CANCER; COLORECTAL CANCER; DRUG BINDING; DRUG CLASSIFICATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; FIBROSARCOMA; GLIOBLASTOMA; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; HYPOTENSION; INJECTION SITE PAIN; KAPOSI SARCOMA; KIDNEY CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; METASTASIS; METASTASIS INHIBITION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; PERITONEUM CANCER; PROSTATE CANCER; RADIATION RESPONSE; REVIEW; RHABDOMYOSARCOMA; SARCOMA; SOFT TISSUE SARCOMA; SOLID TUMOR; TACHYCARDIA; THYROID CARCINOMA; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; UTERINE TUBE CARCINOMA;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL PROLIFERATION; COMBINED MODALITY THERAPY; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TUBULIN MODULATORS;

EID: 84876088405     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2012.10.002     Document Type: Review

References (113)

1. Delaney G., Jacob S., Featherstone C., Barton M. The role of radiotherapy in cancer treatment: estimating optimal utilization from a review of evidence-based clinical guidelines. Cancer 2005, 104:1129-1137.
2. Begg A.C., Stewart F.A., Vens C. Strategies to improve radiotherapy with targeted drugs. Nature Reviews Cancer 2011, 11:239-253.
3. Bhide S.A., Nutting C.M. Recent advances in radiotherapy. BMC Medicine 2010, 8:25.
4. Folkman J. Tumor angiogenesis: therapeutic implications. New England Journal of Medicine 1971, 285:1182-1186.
5. Denekamp J., Hill S.A., Hobson B. Vascular occlusion and tumour cell death. European Journal of Cancer and Clinical Oncology 1983, 19:271-275.
6. Seiwert T.Y., Cohen E.E. Targeting angiogenesis in head and neck cancer. Seminars in Oncology 2008, 35:274-285.
7. Siemann D.W. The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by tumor-vascular disrupting agents. Cancer Treatment Reviews 2010, 37:63-74.
8. Hinnen P., Eskens F.A. Vascular disrupting agents in clinical development. British Journal of Cancer 2007, 96:1159-1165.
9. Siemann D.W., Bibby M.C., Dark G.G., et al. Differentiation and definition of vascular-targeted therapies. Clinical Cancer Research 2005, 11:416-420.
10. O'Reilly M.S. Radiation combined with antiangiogenic and antivascular agents. Seminars in Radiation Oncology 2006, 16:45-50.
11. Heath V.L., Bicknell R. Anticancer strategies involving the vasculature. Nature Reviews Clinical Oncology 2009, 6:395-404.
12. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
13. Rockwell S., Dobrucki I.T., Kim E.Y., et al. Hypoxia and radiation therapy: past history, ongoing research, and future promise. Current Molecular Medicine 2009, 9:442-458.
14. Citrin D., Camphausen K. Advancement of antiangiogenic and vascular disrupting agents combined with radiation. Cancer Treatment and Research 2008, 139:153-171.
15. Shinohara E.T., Maity A. Increasing sensitivity to radiotherapy and chemotherapy by using novel biological agents that alter the tumor microenvironment. Current Molecular Medicine 2009, 9:1034-1045.
16. Siemann D.W., Horsman M.R. Targeting the tumor vasculature: a strategy to improve radiation therapy. Expert Review of Anticancer Therapy 2004, 4:321-327.
17. Horsman M.R., Siemann D.W. Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies. Cancer Research 2006, 66:11520-11539.
18. Samant R.S., Shevde L.A. Recent advances in anti-angiogenic therapy of cancer. Oncotarget 2011, 2:122-134.
19. Patterson D.M., Rustin G.J. Vascular damaging agents. Clinical Oncology (Royal College of Radiologists) 2007, 19:443-456.
20. Thorpe P.E. Vascular targeting agents as cancer therapeutics. Clinical Cancer Research 2004, 10:415-427.
21. Kanthou C., Tozer G.M. Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies. International Journal of Experimental Pathology 2009, 90:284-294.
22. McKeage M.J., Baguley B.C. Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer. Cancer 2010, 116:1859-1871.
23. Tozer G.M., Kanthou C., Parkins C.S., Hill S.A. The biology of the combretastatins as tumour vascular targeting agents. International Journal of Experimental Pathology 2002, 83:21-38.
24. Tozer G.M., Kanthou C., Baguley B.C. Disrupting tumour blood vessels. Nature Reviews Cancer 2005, 5:423-435.
25. Hori K., Saito S. Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis. British Journal of Cancer 2003, 89:1334-1344.
26. Hori K., Saito S., Kubota K. A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs. British Journal of Cancer 2002, 86:1604-1614.
27. Ohno T., Kawano K., Sasaki A., et al. Antitumor and antivascular effects of AC-7700, a combretastatin A-4 derivative, against rat liver cancer. International Journal of Clinical Oncology 2002, 7:171-176.
28. Pettit G.R., Singh S.B., Hamel E., et al. Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. Experientia 1989, 45:209-211.
29. Jordan M.A., Kamath K. How do microtubule-targeted drugs work? An overview. Current Cancer Drug Targets 2007, 7:730-742.
30. Galmarini C.M., Falette N., Tabone E., et al. Inactivation of wild-type p53 by a dominant negative mutant renders MCF-7 cells resistant to tubulin-binding agent cytotoxicity. British Journal of Cancer 2001, 85:902-908.
31. Wahl A.F., Donaldson K.L., Fairchild C., et al. Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. Nature Medicine 1996, 2:72-79.
32. Huang Y.F., Chang M.D., Shieh S.Y. TTK/hMps1 mediates the p53-dependent postmitotic checkpoint by phosphorylating p53 at Thr18. Molecular and Cellular Biology 2009, 29:2935-2944.
33. Li L., Rojiani A.M., Siemann D.W. Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcoma. Acta Oncologica 2002, 41:91-97.
34. Chaplin D.J., Pettit G.R., Parkins C.S., Hill S.A. Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents. British Journal of Cancer Supplement 1996, 27:S86-S88.
35. Hill S.A., Lonergan S.J., Denekamp J., Chaplin D.J. Vinca alkaloids: anti-vascular effects in a murine tumour. European Journal of Cancer 1993, 29A:1320-1324.
36. Holwell S.E., Hill B.T., Bibby M.C. Anti-vascular effects of vinflunine in the MAC 15A transplantable adenocarcinoma model. British Journal of Cancer 2001, 84:290-295.
37. Dark G.G., Hill S.A., Prise V.E., et al. Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor vasculature. Cancer Research 1997, 57:1829-1834.
38. Bertelsen L.B., Shen Y.Y., Nielsen T., et al. Vascular effects of plinabulin (NPI-2358) and the influence on tumour response when given alone or combined with radiation. International Journal of Radiation Biology 2011, 87:1126-1134.
39. Horsman M.R., Murata R. Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response. International Journal of Radiation Oncology, Biology, Physics 2003, 57:1047-1055.
40. Horsman M.R., Murata R., Breidahl T., et al. Combretastatins novel vascular targeting drugs for improving anti-cancer therapy. Combretastatins and conventional therapy. Advances in Experimental Medicine and Biology 2000, 476:311-323.
41. Blakey D.C., Westwood F.R., Walker M., et al. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clinical Cancer Research 2002, 8:1974-1983.
42. Hori K., Saito S., Nihei Y., et al. Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700. Japanese Journal of Cancer Research 1999, 90:1026-1038.
43. Hori K., Saito S., Sato Y., Kubota K. Stoppage of blood flow in 3-methylcholanthrene-induced autochthonous primary tumor due to a novel combretastatin A-4 derivative, AC7700, and its antitumor effect. Medical Science Monitor 2001, 7:26-33.
44. Lunt S.J., Akerman S., Hill S.A., et al. Vascular effects dominate solid tumor response to treatment with combretastatin A-4-phosphate. International Journal of Cancer 2011, 129:1979-1989.
45. Nihei Y., Suzuki M., Okano A., et al. Evaluation of antivascular and antimitotic effects of tubulin binding agents in solid tumor therapy. Japanese Journal of Cancer Research 1999, 90:1387-1395.
46. Nabha S.M., Mohammad R.M., Wall N.R., et al. Evaluation of combretastatin A-4 prodrug in a non-Hodgkin's lymphoma xenograft model: preclinical efficacy. Anti-Cancer Drugs 2001, 12:57-63.
47. Jordan M.A., Wilson L. Microtubules as a target for anticancer drugs. Nature Reviews Cancer 2004, 4:253-265.
48. Blakey D.C., Ashton S.E., Westwood F.R., et al. ZD6126: a novel small molecule vascular targeting agent. International Journal of Radiation Oncology, Biology, Physics 2002, 54:1497-1502.
49. Kamat A.A., Kim T.J., Landen C.N., et al. Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Research 2007, 67:281-288.
50. Schwartz E.L. Antivascular actions of microtubule-binding drugs. Clinical Cancer Research 2009, 15:2594-2601.
51. Risinger A.L., Westbrook C.D., Encinas A., et al. ELR510444, a novel microtubule disruptor with multiple mechanisms of action. Journal of Pharmacology and Experimental Therapeutics 2011, 336:652-660.
52. Murata R., Overgaard J., Horsman M.R. Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues. International Journal of Radiation Biology 2001, 77:195-204.
53. Tozer G.M., Prise V.E., Wilson J., et al. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Research 1999, 59:1626-1634.
54. Subbiah I.M., Lenihan D.J., Tsimberidou A.M. Cardiovascular toxicity profiles of vascular-disrupting agents. Oncologist 2011, 16:1120-1130.
55. Lippert J.W. Vascular disrupting agents. Bioorganic and Medicinal Chemistry 2007, 15:605-615.
56. Hua J., Sheng Y., Pinney K.G., et al. Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate. Anticancer Research 2003, 23:1433-1440.
57. Rice L., Pampo C., Lepler S., et al. Support of a free radical mechanism for enhanced antitumor efficacy of the microtubule disruptor OXi4503. Microvascular Research 2011, 81:44-51.
58. Salmon H.W., Siemann D.W. Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity. Clinical Cancer Research 2006, 12:4090-4094.
59. Mita M.M., Spear M.A., Yee L.K., et al. Phase 1 first-in-human trial of the vascular disrupting agent plinabulin (NPI-2358) in patients with solid tumors or lymphomas. Clinical Cancer Research 2010, 16:5892-5899.
60. Nicholson B., Lloyd G.K., Miller B.R., et al. NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent. Anti-Cancer Drugs 2006, 17:25-31.
61. Watanabe J., Natsume T., Kobayashi M. Comparison of the antivascular and cytotoxic activities of TZT-1027 (Soblidotin) with those of other anticancer agents. Anti-Cancer Drugs 2007, 18:905-911.
62. Cai S.X., Drewe J., Kemnitzer W. Discovery of 4-aryl-4H-chromenes as potent apoptosis inducers using a cell- and caspase-based Anti-cancer Screening Apoptosis Program (ASAP): SAR studies and the identification of novel vascular disrupting agents. Anti-Cancer Agents in Medicinal Chemistry 2009, 9:437-456.
63. Shi W., Siemann D.W. Preclinical studies of the novel vascular disrupting agent MN-029. Anticancer Research 2005, 25:3899-3904.
64. Davis P.D., Dougherty G.J., Blakey D.C., et al. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Research 2002, 62:7247-7253.
65. Hoang T., Huang S., Armstrong E., et al. Augmentation of radiation response with the vascular targeting agent ZD6126. International Journal of Radiation Oncology, Biology, Physics 2006, 64:1458-1465.
66. Landuyt W., Ahmed B., Nuyts S., et al. In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment. International Journal of Radiation Oncology, Biology, Physics 2001, 49:443-450.
67. Murata R., Siemann D.W., Overgaard J., Horsman M.R. Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid. Radiation Research 2001, 156:503-509.
68. Siemann D.W., Rojiani A.M. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. International Journal of Radiation Oncology, Biology, Physics 2002, 53:164-171.
69. Akashi Y., Okamoto I., Suzuki M., et al. The novel microtubule-interfering agent TZT-1027 enhances the anticancer effect of radiation in vitro and in vivo. British Journal of Cancer 2007, 96:1532-1539.
70. Li L., Rojiani A., Siemann D.W. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy. International Journal of Radiation Oncology, Biology, Physics 1998, 42:899-903.
71. Siemann D.W., Rojiani A.M. The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors. International Journal of Radiation Oncology, Biology, Physics 2005, 62:846-853.
72. Landuyt W., Verdoes O., Darius D.O., et al. Vascular targeting of solid tumours: a major 'inverse' volume-response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyosarcomas. European Journal of Cancer 2000, 36:1833-1843.
73. Gabrys D., Greco O., Patel G., et al. Radiation effects on the cytoskeleton of endothelial cells and endothelial monolayer permeability. International Journal of Radiation Oncology, Biology, Physics 2007, 69:1553-1562.
74. Hori K., Furumoto S., Kubota K. Tumor blood flow interruption after radiotherapy strongly inhibits tumor regrowth. Cancer Science 2008, 99:1485-1491.
75. Gorski D.H., Beckett M.A., Jaskowiak N.T., et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Research 1999, 59:3374-3378.
76. Ng Q.S., Goh V., Carnell D., et al. Tumor antivascular effects of radiotherapy combined with combretastatin a4 phosphate in human non-small-cell lung cancer. International Journal of Radiation Oncology, Biology, Physics 2007, 67:1375-1380.
77. Pugh C.W., Ratcliffe P.J. Regulation of angiogenesis by hypoxia: role of the HIF system. Nature Medicine 2003, 9:677-684.
78. Dachs G.U., Steele A.J., Coralli C., et al. Anti-vascular agent combretastatin A-4-P modulates hypoxia inducible factor-1 and gene expression. BMC Cancer 2006, 6:280.
79. Shaked Y., Ciarrocchi A., Franco M., et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 2006, 313:1785-1787.
80. Wilson W.R., Li A.E., Cowan D.S., Siim B.G. Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. International Journal of Radiation Oncology, Biology, Physics 1998, 42:905-908.
81. Murata R., Siemann D.W., Overgaard J., Horsman M.R. Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors. Radiotherapy and Oncology 2001, 60:155-161.
82. Horsman M.R., Murata R. Combination of vascular targeting agents with thermal or radiation therapy. International Journal of Radiation Oncology, Biology, Physics 2002, 54:1518-1523.
83. Horsman M.R., Murata R., Overgaard J. Improving local tumor control by combining vascular targeting drugs, mild hyperthermia and radiation. Acta Oncologica 2001, 40:497-503.
84. Ahmed B., Landuyt W., Griffioen A.W., et al. In vivo antitumour effect of combretastatin A-4 phosphate added to fractionated irradiation. Anticancer Research 2006, 26:307-310.
85. Raben D., Bianco C., Damiano V., et al. Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model. Molecular Cancer Therapeutics 2004, 3:977-983.
86. Wachsberger P.R., Burd R., Marero N., et al. Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma. Clinical Cancer Research 2005, 11:835-842.
87. Ng Q.S., Mandeville H., Goh V., et al. Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck. Annals of Oncology 2012, 23:231-237.
88. Horsman M.R., Murata R., Overgaard J. Combination studies with combretastatin and radiation: effects in early and late responding tissues. Radiotherapy and Oncology 2002, 64:S50.
89. Meng F., Cai X., Duan J., et al. A novel class of tubulin inhibitors that exhibit potent antiproliferation and in vitro vessel-disrupting activity. Cancer Chemotherapy and Pharmacology 2008, 61:953-963.
90. Liberatore A.M., Coulomb H., Pons D., et al. IRC-083927 is a new tubulin binder that inhibits growth of human tumor cells resistant to standard tubulin-binding agents. Molecular Cancer Therapeutics 2008, 7:2426-2434.
91. Dougherty S.T., Walker S.E., Davis P.D., Dougherty G.J. The novel vascular disrupting agent ANG501 induces cell cycle arrest and enhances endothelial cell sensitivity to radiation. Cancer Growth and Metastasis 2009, 2:1-10.
92. Burns C.J., Fantino E., Phillips I.D., et al. CYT997: a novel orally active tubulin polymerization inhibitor with potent cytotoxic and vascular disrupting activity in vitro and in vivo. Molecular Cancer Therapeutics 2009, 8:3036-3045.
93. Burns C.J., Fantino E., Powell A.K., et al. The microtubule depolymerizing agent CYT997 causes extensive ablation of tumor vasculature in vivo. Journal of Pharmacology and Experimental Therapeutics 2011, 339:799-806.
94. Ren X., Dai M., Lin L.P., et al. Anti-angiogenic and vascular disrupting effects of C9, a new microtubule-depolymerizing agent. British Journal of Pharmacology 2009, 156:1228-1238.
95. Pasquier E., Sinnappan S., Munoz M.A., Kavallaris M. ENMD-1198, a new analogue of 2-methoxyestradiol, displays both antiangiogenic and vascular-disrupting properties. Molecular Cancer Therapeutics 2010, 9:1408-1418.
96. Newman S.P., Foster P.A., Stengel C., et al. STX140 is efficacious in vitro and in vivo in taxane-resistant breast carcinoma cells. Clinical Cancer Research 2008, 14:597-606.
97. Kremmidiotis G., Leske A.F., Lavranos T.C., et al. BNC105: a novel tubulin polymerization inhibitor that selectively disrupts tumor vasculature and displays single-agent antitumor efficacy. Molecular Cancer Therapeutics 2010, 9:1562-1573.
98. Chen C.P., Hu C.B., Yeh K.C., et al. Antiangiogenic activities and cisplatin-combined antitumor activities of BPR0L075. Anticancer Research 2010, 30:2813-2822.
99. Kuo C.C., Hsieh H.P., Pan W.Y., et al. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo. Cancer Research 2004, 64:4621-4628.
100. Cai Y.C., Zou Y., Ye Y.L., et al. Anti-tumor activity and mechanisms of a novel vascular disrupting agent, (Z)-3,4',5-trimethoxylstilbene-3'-O-phosphate disodium (M410). Investigational New Drugs 2011, 29:300-311.
101. Cao T.M., Durrant D., Tripathi A., et al. Stilbene derivatives that are colchicine-site microtubule inhibitors have antileukemic activity and minimal systemic toxicity. American Journal of Hematology 2008, 83:390-397.
102. Durrant D., Corwin F., Simoni D., et al. cis-3, 4', 5-Trimethoxy-3'-aminostilbene disrupts tumor vascular perfusion without damaging normal organ perfusion. Cancer Chemotherapy and Pharmacology 2009, 63:191-200.
103. Deng Z.T., Feng T., Wang P., et al. Effects of the novel vascular targeting agent MDS-11P on tumor vascularity and its antitumor activity. Biochemical Pharmacology 2011, 82:1832-1842.
104. Clemenson C., Chargari C., Desire L., et al. Assessment of the novel tubulin-binding agent EHT 6706 in combination with ionizing radiation or chemotherapy. Investigational New Drugs 2012, 30:2173-2186.
105. Clemenson C., Chargari C., Desire L., et al. Erratum to: " Assessment of the novel tubulin-binding agent EHT 6706 in combination with ionizing radiation or chemotherapy". Investigational New Drugs 2012, 30:2451-2453.
106. Luo Y., Hradil V.P., Frost D.J., et al. ABT-751, a novel tubulin-binding agent, decreases tumor perfusion and disrupts tumor vasculature. Anti-Cancer Drugs 2009, 20:483-492.
107. Hsu L.C., Durrant D.E., Huang C.C., et al. Development of hemiasterlin derivatives as potential anticancer agents that inhibit tubulin polymerization and synergize with a stilbene tubulin inhibitor. Investigational New Drugs 2012, 30:1379-1388.
108. Kim T.J., Ravoori M., Landen C.N., et al. Antitumor and antivascular effects of AVE8062 in ovarian carcinoma. Cancer Research 2007, 67:9337-9345.
109. Lara P.N., Douillard J.Y., Nakagawa K., et al. Randomized phase III placebo-controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent vadimezan (ASA404) in advanced non-small-cell lung cancer. Journal of Clinical Oncology 2011, 29:2965-2971.
110. Pili R., Rosenthal M.A., Mainwaring P.N., et al. Phase II study on the addition of ASA404 (vadimezan; 5,6-dimethylxanthenone-4-acetic acid) to docetaxel in CRMPC. Clinical Cancer Research 2010, 16:2906-2914.
111. McKeage M.J., Von Pawel J., Reck M., et al. Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced non-small cell lung cancer. British Journal of Cancer 2008, 99:2006-2012.
112. Garon E.B., Kabbinavar F.F., Neidhart J.A., et al. Randomized phase II trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C), paclitaxel (P), and bevacizumab (B) in stage IIIb/IV nonsquamous non-small cell lung cancer (NSCLC): the FALCON trial. Journal of Clinical Oncology 2010, 28. [suppl; abstr 7587].
113. Sosa J.A., Elisei R., Jarzab B., et al. A randomized phase II/III trial of a tumor vascular disrupting agent fosbretabulin tromethamine (CA4P) with carboplatin (C) and paclitaxel (P) in anaplastic thyroid cancer (ATC): final survival analysis for the FACT trial. Journal of Clinical Oncology 2011, 29. [suppl; abstr 5502].